Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid set-up” for Elanco’s 2025 despite currency headwinds, with the company’s innovation revenue guidance raised by $30M at mid-point on strength in Experior. The post-earnings selloff is a likely a function of limited near-term catalysts, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco Animal Health: Promising Growth Amid FX Challenges and Strong Product Pipeline
- Elanco Animal Health Reports 2024 Earnings and 2025 Outlook
- Morning Movers: Home Depot, Keurig Dr Pepper higher after Q4 results
- Elanco signs agreement with Medgene to commercialize avian influenza vaccine
- Elanco reports Q4 adjusted EPS 14c, consensus 15c